Ruxolitinib (S) Size:Solid 2 mg Bay 11-7085 (ECSCs) significantly inhibits

Bay 11-7085 (ECSCs) significantly inhibits the cell proliferation and DNA synthesis of ovarian endometriotic cyst stromal cells and induces apoptosis and the G0/G1 phase cell cycle arrest of these cells

InChi: InChI=1S/C27H36N2O5

2 µM）and human primary islets (EC50 ~0

is the potent

5(7):720-6

Ruxolitinib (S) Size:Solid 2 mg Bay 11-7085 (ECSCs) significantly inhibitsS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive